Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: Implications of imatinib mesylate

Table 3 Antitumor response and mutation status of 22 advanced and metastatic small bowel GIST patients treated with imatinib meslyate

	CR	PR	SD	PD	P
Exon 9 (n = 3)	0	2	0	1	0.486
Exon 11(n = 13)	0	9	2	2
No mutation (n = 3)	0	3	0	0
Insufficient specimen (n = 3)	0	1	2	0
	Exon 9 (n = 3)		Exon 11 (n = 13)		1.0
PR, n (%)	2 (66.7)		9 (69.2)
SD + PD, n (%)	1 (33.3)		4 (30.8)

PR: Partial response; SD: Stationary disease; PD: Progression of disease.